Emyria partners with PAX Centre for MDMA-assisted therapy
Released
Released
Announcement PDF
ASX Announcement
07 Mar 2023
Emyria partners with specialist trauma psychiatric
service to advance MDMA-assisted therapy
HIGHLIGHTS
Emyria and PAX Centre to develop a scalable MDMA-assisted therapy model for patients
with complex PTSD
PAX Centre is one of Australia’s leading trauma-focused, multidisciplinary psychiatric
services specialising in the treatment of complex trauma
Collaboration is part of Emyria’s longer-term goal to establish a network of trained therapists
and psychiatrists to provide MDMA-assisted therapy - via ethics approved clinical trials and the
Authorised Prescriber pathway - to appropriately diagnosed patients from July 1st 2023
Emyria Limited (ASX: EMD), a clinical stage biotech company, has announced a
collaboration with The Pax Centre (PAX), Australia's leading multidisciplinary, psychiatrist-led
clinical service specialising in complex trauma treatment.
The collaboration aims to develop a scalable care program for the safe provision of
MDMA-assisted therapy, in the community, for patients with treatment resistant PTSD.
PAX will provide specialist psychiatrists, trained therapists, and facilities. Emyria will manage
clinical trial design, Real-World Data generation, data monitoring and MDMA supply
following the recent securing of patient-ready MDMA. [1] The care program will commence as
an ethics-approved clinical trial (with Emyria as Sponsor) until PAX psychiatrists have
obtained Authorised Prescriber status and a cost model has been developed. The care
program could support other specialist groups under licence.
PTSD is a significant mental health issue in both the United States and Australia. In the
US, approximately 10 million people are estimated to suffer from PTSD with total excess
economic burden costs estimated to be around $232.2 billion per year. [2]
In Australia, approximately 1 million people are estimated to suffer from PTSD. Given around
30-50% of PTSD patients show resistance to standard treatment there has been increasing
interest in novel treatment approaches. [3]
MDMA-assisted therapy has shown promising results for patients with PTSD [4] but
its use has been limited to research settings due to the extensive preparations required
encompassing therapist training, clinical protocol design, facility preparation, data
monitoring, and drug supply coordination.
Emyria ASX Announcement | 07 Mar 2023
1
Emyria’s Managing Director, Dr Michael Winlo said: “As the burden of PTSD grows, the
interest and demand for new treatment options increases amongst patients and specialists.
Following the TGA’s recent decision to reschedule MDMA to a controlled medicine, we believe
the demand amongst psychiatry groups for a safe, cost-effective, and evidence-based care
program to deliver MDMA-assisted therapy in the community for suitably screened patients.
Emyria is thrilled to collaborate with The Pax Centre, a leading psychiatric clinical service, to
develop this care program. Our team looks forward to developing clinical protocols with their
experts that may help patients with PTSD while generating Real World Data that can support
ongoing program improvement as well as Emyria’s novel drug development program.”
Starting from July 1st, 2023, the TGA’s Authorised Prescriber Program in Australia
will allow patient access to MDMA-assisted therapy as a Schedule 8 controlled medicine [5].
However, as stated by the Royal Australian and New Zealand College of Psychiatrists,
“prescribing psychiatrists must demonstrate adequate training, evidence-based treatment
protocols, patient selection, and monitoring to be approved to prescribe this therapy.
Ongoing psychotherapeutic support is also essential for this treatment model.” [6]
Emyria's partnership with PAX aims to directly address these challenges by developing a
scalable care program for MDMA-assisted therapy that can be safely and cost-effectively
administered to patients with PTSD through community psychiatry groups. Emyria will
develop the clinical delivery and data monitoring protocols while PAX will provide specialists
and trained therapists, and an appropriate facility to administer the therapy safely.
Emyria has already secured a supply of patient-ready MDMA [1]
Emyria believes a comprehensive clinical package (eg program + drug supply) has the
potential to be licensed to other specialist groups wishing to participate in the network to help
support the nearly 500,000 Australian patients with treatment-resistant PTSD.
PAX Centre Director, Psychiatrist Dr Jon Laugharne said: "Caring for patients with
complex trauma can be incredibly challenging, and we have had to close our books to
new patients due to both the size of the problem and the relatively low remission rates
with
current
treatments.
Working in this space is complex, with so many unknowns, but we are pleased to have
the support of Emyria to help us navigate these challenges and bring this exciting and
innovative treatment to those patients who need it most."
PAX Centre Director, Mental Health Nurse Claire Kullack said:
"This collaboration strongly aligns with our mission to provide the best possible care and
outcomes for our patients and to continually seek out and adopt new, evidence-based
treatments.
As one of the leading services tackling complex trauma in Australia, we have always
prided ourselves on being at the forefront of innovative and multidisciplinary approaches
to care. We are excited to partner with Emyria to explore the feasibility of this promising
new treatment option for our patients with PTSD."
Emyria ASX Announcement | 07 Mar 2023
2
The Real World Data to be generated in this partnership will support ongoing care model
improvements, crucial cost-effectiveness studies to support reimbursement and also Emyria’s
active MDMA-inspired drug development program with partner the University of Western
Australia.
Emyria’s novel, MDMA-inspired drug discovery program is looking to create new medicines,
and currently, leading programs are working on the following:
●
●
Faster acting MDMA-like compound with the potential to shorten treatment session
times and increase the number of patients treated and;
A novel therapy to ameliorate the symptoms of Parkinson’s disease treatment.
The recent rescheduling of MDMA by the TGA further supports Emyria’s novel
MDMA-inspired drug development program by opening a pathway to registration and
reimbursement for these novel compounds across a range of neuropsychiatric disorders.
Emyria is advancing its drug discovery program in Australia and the United States to
identify novel, MDMA-like compounds with therapeutic potential, while collaborating with local
clinical partners to improve patient access and ongoing research.
UPCOMING MILESTONES
CLINICAL PROGRAMS
“direct-to-consumer”
“prescription medicine”
PRE-CLINICAL + THERAPY PROGRAMS
New Drug Discovery
MDMA-assisted therapy
Formulation
optimisation (RX5)
Formulation
optimisation (RX7)
Continuous creation
& screening
Protocol developed
Phase 1 study done
Phase 1
First patent family filed
Clinical partnerships
Phase 3
commencement
Pre-IND (FDA)
US-focused
preclinical program
Real-World Data system
Regulatory submission
Pivotal trials
Metabolic studies
MDMA supply secured
Lead selection
Therapist training
Phase 1 trials
First patient
Global commercial strategy
Global commercial strategy
Commercial strategy Australia
Commercial strategy Europe
Commercial strategy USA
FOR FURTHER INFORMATION
Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
1.
2.
3.
4.
5.
6.
Lexi O’Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com
This release has been approved by the Board of Emyria.
Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com
Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au
See ASX release 13 Feb 2023
Davis LL, Schein J, Cloutier M, et al. The economic burden of posttraumatic stress disorder in the United
States from a societal perspective. J Clin Psychiatry. 2022;83(3):21m14116
https://www.phoenixaustralia.org/
Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized,
double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033 (2021)
https://www.tga.gov.au/sites/default/files/2023-02/notice-of-final-decision-to-amend-or-not-amend-the-cur
rent-poisons-standard-june-2022-acms-38-psilocybine-and-mdma.pdf accessed 05 Feb 2023
https://www.ranzcp.org/news-policy/news/change-to-classification-of-psilocybin-and-mdma
Emyria ASX Announcement | 07 Mar 2023
3
ABOUT EMYRIA | emyria.com
Emyria Limited is a clinical drug development and care delivery company focused on accelerating
drug development and improving patient outcomes in neuroscience and mental health via:
●
Drug Development: Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for
registration against multiple indications. Emyria’s first dose form, EMD-RX5, is in Phase 3 trials.
●
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest
libraries of MDMA-like compounds with partner, the University of Western Australia.
●
Proprietary Real-World Data (RWD): Emyria gathers robust and ethically-sourced data with
patients cared for at Emyria’s own specialist clinical service (Emerald Clinics).
Emyria RWD can help support drug development and care model improvement.
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking
questions and comments, which our team can respond to where possible.
ABOUT PAX Centre | paxcentre.com.au
The Pax Centre (‘PAX’) provides expert assessment and treatment for those suffering from the
psychological impact of traumatic life experiences.
PAX offers an individualised approach to assessing and treating people suffering from the effects of
traumatic life experiences. Such experiences can result in various mental health problems including
post-traumatic stress disorder (PTSD), complex PTSD and dissociation, depression, other anxiety
disorders, chronic adjustment reactions, somatic syndromes and abuse of alcohol or drugs.
Traumatic experiences can include a wide range of life events, such as physical or sexual assault,
natural disasters, medical procedures, sudden bereavements or wartime incidents. Whilst most
people can, and do, recover from such experiences with the support of family and friends, some will
develop significant problems which can have a major effect on their day-to-day lives, often affecting
their work and relationships.
Complex trauma differs from single-incident trauma in that it is a multifaceted syndrome
where the traumatic event(s) were relational, repeated, and cumulative; and it usually occurs at
developmentally sensitive stages of neurological maturation. For this reason, the social, emotional,
behavioural and interpersonal effects of childhood trauma are often pervasive and continue to affect
many different areas of people’s adult lives long after the original trauma has passed and/or been
debriefed. PAX have found that when these situations arise, an early assessment, diagnosis and the
initiation of appropriate evidence-based treatment strategies is vital.
In addition to this, PAX teach proactive, preventative and health expanding strategies to enable the
personal growth, improved well-being and performance of our clients. Empowering PAX clients
through the acquisition of new skills and tools is the focus of our philosophy.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future
expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may
differ materially from those indicated by such forward-looking statements as a result of various important factors, including:
the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the
Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements
included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent
events and developments will cause the Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the
date hereof.
Emyria ASX Announcement | 07 Mar 2023
4
Share your feedback
Discover